Balyasny Asset Management
VC Fund
Chicago, United States
Balyasny Asset Management (BAM) is a diversified global investment firm founded in 2001 by Dmitry Balyasny, Scott Schroeder, and Taylor O'Malley. With over $37 billion in assets under management, BAM employs more than 2,800 people across 24 offices in the U.S. and Canada, Europe, the Middle East, and Asia. The firm’s investment teams span five strategies, including Equities Long/Short, Fixed Income & Macro, Commodities, Multi-Asset Arbitrage, and Systematic. Balyasny’s mission is to deliver to its investors absolute, uncorrelated returns in all market environments.
- Total investments:
- 54
- Last investment:
- Lead investor:
- 9%
- Fund size:
- $2.5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Balyasny Asset Management invests in
Stages Balyasny Asset Management invests in
Countries Balyasny Asset Management invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 10 contacts → | |||
Round size
- Series A
- $6.1M–$179M
- Series D
- $35M–$225M
- Post-IPO Equity
- $35M–$197M
Investment Focus
Industry
- Biotechnology 27 (50%)
- Health Care 16 (30%)
- Biopharma 11 (20%)
- Pharmaceutical 11 (20%)
- Therapeutics 9 (17%)
Stage
- Post-IPO Equity 17 (31%)
- Series A 8 (15%)
- Series D 7 (13%)
- Series C 5 (9%)
- Series B 3 (6%)
Country
- United States 40 (74%)
- China 2 (4%)
- Latvia 1 (2%)
- Sweden 1 (2%)
- Belgium 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Magnell
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
Brad Downes
Associate Director - Strategic Finance
|
Associate Director - Strategic Finance | Total investments: 0 | Find email | |
David Black
Managing Director Business Development
|
Managing Director Business Development | Total investments: 0 | Find email | |
David Shaw
Senior Analyst
|
Senior Analyst | Total investments: 0 | Find email | |
Douglas Cilento
Head of Macro Trading
|
Head of Macro Trading | Total investments: 0 | Find email | |
| See all 10 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $135M / Series B / Oct 13, 2026 | ||
| Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with thegoal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. | $150M / Post-IPO Equity / Aug 21, 2026 | ||
| Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $132M / Post-IPO Equity / Jul 16, 2026 | ||
| Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M / Series D / Jun 25, 2026 | ||
| Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines. | $32.5M / Series A / Jun 01, 2026 | ||
| Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $115M / Post-IPO Equity / May 18, 2026 | ||
| Cellectar Biosciences, a radiopharmaceutical company, designs and develops products to detect, treat, and monitor various human cancers. Its products include 131I-CLR1404, a compound for cancer therapy. The company's product candidates combine lipid-like molecules and phospholipid ethers analogs with radioisotopes to image or destroy malignantcells.Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin. | $35M / Post-IPO Equity / May 05, 2026 | ||
| Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | ||
| Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a pipeline of proprietary FASNinhibitors. | $175M / Post-IPO Equity / Apr 27, 2026 | ||
| Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $150M / Post-IPO Equity / Apr 16, 2026 | ||
| See all 54 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Balyasny Asset Management invest in?
Balyasny Asset Management invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Post-IPO Equity and Series A stage. Most of the 54 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Balyasny Asset Management invest in?
Balyasny Asset Management typically joins rounds of $6.1M–$179M at Series A, $35M–$225M at Series D and $35M–$197M at Post-IPO Equity. These are whole funding-round sizes, not Balyasny Asset Management's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Balyasny Asset Management took part in.
How do I contact Balyasny Asset Management?
Public channels for Balyasny Asset Management include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Balyasny Asset Management?
The team at Balyasny Asset Management includes Michael Magnell (Senior Analyst), Brad Downes (Associate Director - Strategic Finance) and David Black (Managing Director Business Development), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
